Cargando…
Perspectives on Treatment Burden for Methotrexate and Tumor Necrosis Factor Inhibitors Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis: A Qualitative Study
OBJECTIVE: To describe patients’ perspectives on the burden associated with methotrexate (MTX) or tumor necrosis factor inhibitor (TNFi) use in psoriatic arthritis (PsA) and rheumatoid arthritis (RA). METHODS: Between May 2019 and March 2020, patients receiving MTX and/or a TNFi for either PsA or RA...
Autores principales: | Ogdie, Alexis, Shaw, Yomei, Almonte, Michele, Maksabedian Hernandez, Ervant J., Stolshek, Bradley, Michaud, Kaleb |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100692/ https://www.ncbi.nlm.nih.gov/pubmed/36762609 http://dx.doi.org/10.1002/acr2.11530 |
Ejemplares similares
-
Side Effects of Methotrexate and Tumor Necrosis Factor Inhibitors: Differences in Tolerability Among Patients With Psoriatic Arthritis and Rheumatoid Arthritis
por: Ogdie, Alexis, et al.
Publicado: (2022) -
Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination
por: Strand, Vibeke, et al.
Publicado: (2021) -
The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis
por: Incerti, Devin, et al.
Publicado: (2020) -
Probiotic Use and Psoriatic Arthritis Disease Activity
por: Grinnell, Madison, et al.
Publicado: (2020) -
Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data
por: Gharaibeh, Mahdi, et al.
Publicado: (2020)